Adial Pharmaceuticals, Inc. has announced another adjournment of its 2026 Annual Meeting of Stockholders due to delays in obtaining Nasdaq's approval for its Initial Listing Application. This situation has significant implications for the company and its stakeholders, as key proposals requiring shareholder votes remain unresolved.
The company convened its Annual Meeting on September 17, 2026, but could not proceed with all proposals because it had not received the necessary approvals from Nasdaq. As a result, the meeting was adjourned to allow more time for these approvals. On October 1, 2026, the company reconvened the meeting but again had to adjourn due to the lack of approval.
On October 15, 2026, the company reconvened the meeting once more but chose to further adjourn discussions on Proposals 3, 4, 5, and 6 until October 26, 2026. The polls for these proposals remain open, and stockholders who have already cast their votes do not need to take further action unless they wish to change their votes.
This ongoing delay underscores the challenges faced by companies in the pharmaceutical preparations industry, particularly in navigating regulatory requirements and obtaining necessary approvals. The adjournment could also impact investor confidence and the company’s operational plans moving forward.
The upcoming reconvened meeting is scheduled for October 26, 2026, at 8:30 a.m. Eastern Time, at the company’s offices in Charlottesville, Virginia. Stakeholders are encouraged to stay updated on developments as the situation unfolds.
For further details, stockholders can refer to the definitive proxy statement filed with the SEC on August 24, 2026, which outlines the proposals to be voted on.